Forschung & Innovation
Publikationen
The OligoPanc project
PMU Autor*innen
Sabine Gerum, Falk Roeder
Alle Autor*innen
Carl-Stephan Leonhardt, Mustapha Adham, Shouki Bazarbashi, Irit Ben-Aharon, Regina G. H. Beets-Tan, Ugo Boggi, Thomas B. Brunner, Francesco Cellini, Arturo Chiti, Lois Daamen, Berardino De Bari, Sara De Dosso, Michel Ducreux, Cathy Eng, Massimo Falconi, Cristina R. Ferrone, Isabella Frigerio, Ingrid Garajova, Sabine Gerum, Michael Ghadimi, Thomas Gruenberger, Pascal Hammel, Karin Haustermans, Maria Hawkins, Jin He, Hanne D. Heerkens, Florence Huguet, Martijn P. W. Intven, Ulla Klaiber, Tiuri E. Kroese, Pierre Laurent-Puig, Florian Lordick, Ethan B. Ludmir, Teresa Macarulla, Oscar Matzinger, Alessio G. Morganti, Somnath Mukherjee, Eileen M. O'Reilly, Joon Oh Park, Demetris Papamichael, Per Pfeiffer, Jose M. Ramia, Falk Roeder, Erika Ruiz-Garcia, Sohei Satoi, Marta Scorsetti, Martin Schneider, Thomas Seufferlein, Alejandro Serrablo, Shailesh V. Shrikhande, Elizabeth C. Smyth, Magali Svrcek, Kyoichi Takaori, Margaret A. Tempero, Natalia S. Tissera, Jeanne Tie, Orlando J. M. Torres, Anthony Turpin, Eric Van Cutsem, Eva Versteijne, Caterina Vivaldi, Zev A. Wainberg, Ralph R. Weichselbaum, Juergen Weitz, Christopher L. Wolfgang, Gerald W. Prager, Oliver Strobel
Fachzeitschrift
LANCET ONCOL
Kurzfassung
Currently, no consensus exists regarding the definition of oligometastatic pancreatic ductal adenocarcinoma, its necessary diagnostic measures, and potential treatment approaches. To address these knowledge gaps, the OligoPanc project brought together an interdisciplinary group of experts to establish consensus using a modified Delphi process and clinical vignettes. Participants agreed that the number of metastatic lesions and the number of affected organs are key elements in defining oligometastatic pancreatic ductal adenocarcinoma. Specifically, up to three lesions in a single organ, either the liver or the lung, define oligometastatic pancreatic ductal adenocarcinoma and could be either synchronous or metachronous. Necessary diagnostics include a triple-phase contrast-enhanced CT scan of the chest and abdomen and MRI of the liver with a hepatocyte-specific contrast agent. In unclear cases, [F-18]fluorodeoxyglucose-PET CT or MRI can be considered. A multidisciplinary tumour board is essential. Patient-intrinsic factors, including age, do not define oligometastatic disease but should be considered for any treatment decision. Systemic treatment before any local consolidative treatment, including surgery, stereotactic ablative radiotherapy, or other locally ablative techniques, is mandatory. The proposed definition should be incorporated into future trials to improve comparability and enable validation.
Keywords
SOCIETY, Oncology